Effects of Dexmedetomidine Combined with Sufentanil on P2X7 Receptor Expression in Peripheral Blood Mononuclear Cells in Patients with Burn Pain
To explore the effect of dexmedetomidine combined with sufentanil in the treatment of burn pain and its effect on monocyte P2X7 receptor expression. 152 patients in the Burns of our hospital from December 2015 to December 2017 were selected, numbered according to the patient’s admission order and the odd-even method was divided into control group (76 cases) with sufentanil analgesia treatment, observation group (76 cases) dexmedetomidine combined with sufentanil analgesia. Comparing the two groups of patients with arterial blood pressure and other basic vital signs, sedation and pain score oxidative stress index and P2X7 receptor expression in peripheral blood mononuclear cells. SBP, DBP and HR were significantly decreased in the two groups after treatment (P<0.05), but no significant difference (P<0.05). Compared with those before treatment, the pain scores of all periods decreased significantly (P<0.05), and the observation group was significantly lower (P<0.05). The pain scores showed a decreasing trend in each time period within the observation group and the difference was obvious (P<0.05). The sedation scores at 10 min, 30 min and 60 min after administration were obviously different (P<0.05), and the sedation scores reached the maximum at 10 min, but there was no significant difference in sedation scores between the two groups at 5 min after dosing(P>0.05). In the observation group, Serum stress responses were significantly decreased (P<0.05), but the control group was not (P>0.05). Flow cytometry showed that the expression of P2X7 receptor in CD14 cells was significantly decreased in the observation group (P<0.05), while the control group was not (P>0.05). Dexmedetomidine combined with sufentanil has an obvious analgesic effect on burn patients, not aggravated the inhibition of the heart function, and it can significantly reduce the stress response and the expression of P2X7 receptor, should be clinically popularized.